You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Patients’ characteristics. NR (Not recorded). PS (Performance status)* (Additional file 8 [21]), EGFR (epidermal growth factor receptor), EGFR mutation (epidermal growth factor receptor with a sensitizing mutation to targeted therapy), ALK (anaplastic lymphoma kinase), Kras (K-rat sarcoma), WT (wild type) meaning no sensitizing mutations are found. cCRT (concurrent chemoradiotherapy), sCRT (sequential chemoradiotherapy). RT (radiotherapy). 4 cycles of chemotherapy are usually given. CV (cisplatin and vinorelbine), CarboV (carboplatin and vinorelbine), GCis (gemcitabine and cisplatin), GCarb (gemcitabine and carboplatin), Pemcarbo (pemetrexed and carboplatin), CisN (cisplatin and navelbine). AE (adverse event)

From: A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer

Patient Age range PS Stage Histology Treatment
1 45-49y PS1 IIIA Squamous cell carcinoma cCRT (CVx4; 64Gy in 32#)
2 65-69y PS0 IIIA Squamous cell carcinoma sCRT (GCarb × 4; 64Gy in 32#)
3 70-74y PS1 IIIA Squamous cell carcinoma cCRT (CV ×1-stopped due to AE; 64Gy in 32#)
4 70-74y PS1 IIIA Squamous cell carcinoma sCRT (GCis ×4; 55 Gy in 20#)
5 80-84y PS1 IIIA Adenocarcinoma. EGFR WT sCRT (pemcarbo ×2- stopped due to AE; 64Gy in 32#)
6 55-59y PS1 IIIA Adenocarcinoma EGFR WT cCRT (CV ×4, 64Gy in 32#)
7 70-74y PS1 IIIB Squamous cell carcinoma sCRT (GCarbo ×3- stopped due to AE; 55Gy in 20#)
8 65-69y PS0 IIIA Squamous cell carcinoma cCRT (CVx3; 55gy in 20#)
9 65-69y NR IIIA Squamous cell carcinoma RT alone: 55gy in 20#
10 55-59y NR IIIA Squamous cell carcinoma RT alone: 64Gy in 32#
11 65-69y NR IIIB Squamous cell carcinoma sCRT (GCisx2 switched to GCarbo x 2 due to AE; 64Gy in 32#
12 65-69y NR IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4, 64Gy in 32#)
13 75-79y PS1 IIIA Adenocarcinoma. EGFR mutation Gefitinib ×6 followed by 55 in 20#
14 65-69y PS0 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CVx1 switched to CarboV ×3 due to AE; 64Gy in 32#)
15 65-69y PS1 IIIA High grade dysplasia at least; no definitive invasive malignancy cCRT (CV ×4; 64Gy in 32#)
16 55-59y PS1 IIIA Squamous cell carcinoma cCRT (CV ×2; 64Gy in 32#)
17 70-74y NR IIIB Adenocarcinoma. EGFR and ALK WT RT alone: 64Gy in 32#
18 75-79y PS0 IIIB Adenocarcinoma. EGFR and ALK WT cCRT (CisN; 64Gyin 32#)
19 80-84y PS2 IIIB Squamous cell carcinoma RT alone: 64Gy in 32#
20 50-54y PS1 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4; 64Gy in 32#)
21 50-54y PS0 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×3; 64Gy in 32#)
22 55-59y PS1 IIIB Adenocarcinoma. EGFR and ALK WT RT alone: 64Gy in 32#
23 70-74y PS1 IIIA Squamous cell carcinoma RT alone: 55Gy in 20#
24 75-79y PS1 IIIA Adenocarcinoma. EGFR and ALK WT sCRT (CVx4; 64Gy in 32#)
25 80-84y PS1 IIIA PD carcinoma(no comment on EGFR/ALK) RT alone: 55Gy in 20#
26 60-64y PS0 IIIA Adenocarcinoma. EGFR and ALK WT sCRT (CV ×2 switched to CarboV ×2 due to AE; 64Gy in 32#)
27 80-84y PS0 IIIA Squamous cell carcinoma cCRT (CV ×4; 64Gy in 32#)
28 45-49y PS1 IIIB Squamous cell carcinoma cCRT (CV ×4; 64Gy in 32#)
29 65-69y PS1 IIIA Squamous cell carcinoma cCRT (CarboVx3; 64Gy in 32#)
30 45-49y PS1 IIIA Adenocarcinoma-insufficient material for ALK/EGFR testing sCRT (cispem ×4; 64Gy in 32#)
31 65-69y PS0 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4; 64Gy in 32#)
32 60-64y PS1 IIIA Adenocarcinoma. EGFR and ALK WT sCRT (cispemx2 switched to CV ×2 due to AE; 64Gy in 32#)
33 60-64y PS1 IIIB Squamous cell carcinoma cCRT (CV ×4; 64Gy in 32#)
34 70-74y PS1 IIIB Squamous cell carcinoma RT alone: 64Gy in 32#
35 60-64y PS1 IIIB Adenocarcinoma. EGFR and ALK WT, KRAS mutation cCRT (CV ×4; 64Gy in 32#)
36 45-49y PS1 IIIA NSCLC-not possible to further differentiate tumour type cCRT (CV ×4; 64Gy in 32#)
37 70-74y PS2 IIIA Squamous cell carcinoma RT alone: 55Gy in 20#
38 65-69y PS1 IIIB Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4; 64Gy in 32#)
39 55-59y PS1 IIIB Adenocarcinoma. EGFR and ALK WT cCRT (CV ×6; 64Gy in 32#)
40 80-84y PS1 IIIA Adenocarcinoma RT alone: 55Gy in 20#
41 75-79y NR IIIB Adenocarcinoma. EGFR and ALK WT RT alone: 64Gy in 32#; declined chemotherapy
42 60-64y PS2 IIIA Adenocarcinoma. EGFR and ALK WT RT alone: 55Gy in 20#
43 85-89y PS1 IIIA Squamous cell carcinoma RT alone: 55Gy in 20#